Bertrand Ducurtil - Neurones Managing Director

NRO Stock  EUR 44.90  0.05  0.11%   

Managing Director

Mr. Bertrand Ducurtil has served Executive Vice Chairman of the Board of Neurones SA since June 8, 2017. He was previously Deputy CEO and Director of the company from June 30, 1999. He also serves as a Member of the Supervisory Board of Host Developpement and CEO of Neurones Consulting. since 2017.
Age 63
Tenure 7 years
Phone33 1 41 37 41 37
Webhttps://www.neurones.net

Neurones Management Efficiency

The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1403 %, meaning that it generated $0.1403 on every $100 dollars invested by stockholders. Neurones' management efficiency ratios could be used to measure how well Neurones manages its routine affairs as well as how well it operates its assets and liabilities.
Neurones has accumulated 27.82 M in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Neurones has a current ratio of 2.48, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Neurones until it has trouble settling it off, either with new capital or with free cash flow. So, Neurones' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Neurones sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Neurones to invest in growth at high rates of return. When we think about Neurones' use of debt, we should always consider it together with cash and equity.
Neurones S.A., an information technology services company, provides infrastructure, application, and consulting services in France and internationally. Neurones S.A. was founded in 1985 and is headquartered in Nanterre, France. NEURONES operates under Information Technology Services classification in France and is traded on Paris Stock Exchange. It employs 5160 people. Neurones (NRO) is traded on Euronext Paris in France and employs 5,961 people.

Management Performance

Neurones Leadership Team

Elected by the shareholders, the Neurones' board of directors comprises two types of representatives: Neurones inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurones. The board's role is to monitor Neurones' management team and ensure that shareholders' interests are well served. Neurones' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurones' outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthieu Vautier, Chief Officer
Bertrand Ducurtil, COO, Executive VP, Deputy Managing Director, Associate Director and Director
PaulCsar Bonnel, Adm director
Luc Chammard, Chairman, CEO and Associate Director

Neurones Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurones a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Neurones Stock

Neurones financial ratios help investors to determine whether Neurones Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Neurones with respect to the benefits of owning Neurones security.